Physician profile
Timothy W Mark
NPI 1588725006
$7,181.60
in general payments reported to CMS, 2019-2025
49 companies · $1,369 in 2025
The $1,369 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,216 · 2020: $237 · 2021: $821 · 2022: $1,040 · 2023: $1,361 · 2024: $1,139 · 2025: $1,369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,794 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,793.93 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $963.08 | 2019-2025 | |
| Amgen INC. | $795.76 | 2019-2025 | Evenity, Prolia, Repatha |
| Lilly USA, LLC | $766.04 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $395.09 | 2019-2025 | Breztri, Airsupra |
| Abbvie INC. | $381.76 | 2021-2023 | |
| Exact Sciences Corporation | $283.54 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $251.21 | 2019-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Merck Sharp & Dohme LLC | $234.15 | 2019-2022 | |
| Novo Nordisk INC | $231.69 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Sumitomo Pharma America, INC. | $223.46 | 2023-2025 | Gemtesa, Myfembree |
| Janssen Pharmaceuticals, INC | $220.51 | 2019-2024 | Xarelto |
| Radius Health, INC. | $198.05 | 2023-2025 | Tymlos |
| Otsuka America Pharmaceutical, INC. | $173.54 | 2023-2025 | Rexulti |
| Abbott Laboratories | $153.36 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Bayer Healthcare Pharmaceuticals INC. | $153.05 | 2022-2025 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Mark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.